Rhode Island

The state has published the date it stops paying. Its memorandum to Medicaid providers states: "Pursuant to the Rhode Island State Fiscal Year 2027 Enacted Budget, beginning October 1, 2026, Rhode Island Medicaid will no longer cover certain GLP-1 receptor agonists when they are prescribed solely for weight loss." It then names them: Foundayo (Orforglipron), Saxenda (Liraglutide), Wegovy (Semaglutide) and Zepbound (Tirzepatide).

Rhode Island Executive Office of Health and Human Services, Memorandum to RI Medicaid Providers, "GLP-1 State Budget Guidance", effective August 2026 · source

The change is about the reason for the prescription, and a route stays open. The same memorandum says: "If continued treatment with one of these medications listed above is medically necessary for an indication other than weight loss, providers must submit a new PA request with the appropriate clinical documentation." It adds that "For members younger than 21 years of age, all PA requests must be reviewed for medical necessity in accordance with Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) requirements."

Rhode Island Executive Office of Health and Human Services, Memorandum to RI Medicaid Providers, "GLP-1 State Budget Guidance", effective August 2026 · source

The state repeated the notice in its own provider newsletter, which is how a reader can date it independently of the memorandum. The September 2026 Provider Update carries the identical paragraph under the heading "GLP-1 State Budget Guidance", and lists the change among the "Fiscal Year 2027 Medicaid Budget Initiatives" the agency is implementing.

Rhode Island Medicaid, Provider Update, September 2026 (Vol 404), effective September 2026 · source

On the list in force when this was read, Wegovy is the state's preferred weight-management agent and everything else in the class is not. Under "Weight Management Agents" the drug list states "Clinical Prior Authorization Required for Entire Class/Manual PA" and "Length of Authorization: 1 Year", with a "Current Review Date: 5/19/2026". The preferred column holds one entry, Wegovy. The non-preferred, prior-authorization column holds liraglutide, orlistat capsule, phentermine/topiramate, Foundayo, Imcivree, Saxenda (SQ), Wegovy HD (SQ), Wegovy tablets, Xenical and Zepbound.

Rhode Island Executive Office of Health and Human Services, Fee-for-Service Preferred Drug List, revised 6/16/2026, effective June 2026 · source

Rhode Island measures success in pounds rather than percentages, and it asks at one month. Its weight-reduction prior authorization form grants "INITIAL COVERAGE MONTHS 1 – 3" and then requires, in capitals on the form, "MUST HAVE 4 LB. WEIGHT LOSS AT END OF 1ST MONTH" and "MUST MAINTAIN OR EXCEED 1ST MONTH WEIGHT LOSS AT THE END OF MONTH 3." Two further stages follow, months 4–6 and months 7–11, each measured against the month-3 result. The form also states it is "NOT required for recipients less than 21 years of age" and warns that "REQUESTS LACKING ALL REQUIRED INFORMATION LISTED BELOW WILL BE DENIED."

Rhode Island Executive Office of Health and Human Services, form PA04 — Weight Reduction Request, revised 09.25.2025, effective September 2025 · source

The managed care rulebook is silent on this class, which means the change is coming from the budget rather than from that contract. Rhode Island's Medicaid Managed Care Manual chapter on pharmacy protocols, effective 1/1/2026, lists fourteen pharmacy exclusions and names erectile dysfunction drugs among them; a search of the whole 12,752-character chapter found no occurrence of "weight", "obes", "anorexi", "GLP", or any of the four drug names, against control terms "insulin" (3) and "cosmetic" (1). The chapter also states that "the Contractor may maintain its own proprietary preferred drug list (PDL)" within the brand-name classes it allows.

Rhode Island Executive Office of Health and Human Services, EOHHS Medicaid Managed Care Manual, Chapter 2.4 — Medicaid Managed Care Pharmacy Benefit Plan Protocols, Version 1.1, effective January 2026 · source

Keeping the drug while you appeal is a much shorter clock than appealing, and it is the one Rhode Island publishes plainly. The state's appeals rule sets the aid-pending advance notice period for "All Medicaid" at "10 days beginning on the fifth day after the date on the notice of intended action." For members who have been through a managed care plan's own process first, the rule states that "The final federal managed Medicaid rules allow beneficiaries 120 calendar days to request a fair hearing." We could not find a filing window stated for a fee-for-service pharmacy denial: every other day-count in the Part is a decision timeline or another program's rule, so this page states none.

Rhode Island Code of Regulations 210-RICR-10-05-2, Complaints, Grievances and Appeals, effective January 2022 · source

An older layer of the pharmacy manual is still published and still says something different, which is worth knowing before quoting it. The state's legacy pharmacy coverage policy page lists the drug types outside the scope of the program and includes "Anorexiants (all types, limited to a three-month approval only)" — the source prints no period there, and the list continues. The page carries no date on its face, and the three-month limit it describes is not the structure the current PA04 form uses.

Rhode Island Executive Office of Health and Human Services, Medicaid Provider Manual — Pharmacy Coverage Policy · source